Inventor
Türeci Özlem
DE43 patents
⚠️ This page may combine multiple inventors who share the name “Türeci Özlem”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
GANYMED PHARMACEUTICALS AG
14 patentsUS9751934B2Sep 5, 2017
Monoclonal antibodies against claudin-18 for treatment of cancer
GANYMED PHARMACEUTICALS AG13 citations91
US10137195B2Nov 27, 2018
Therapy involving antibodies against Claudin 18.2 for treatment of cancer
GANYMED PHARMACEUTICALS AG7 citations84
US10174104B2Jan 8, 2019
Monoclonal antibodies against claudin-18 for treatment of cancer
GANYMED PHARMACEUTICALS AG3 citations83
US9512232B2Dec 6, 2016
Antibodies against Claudin 18.2 useful in cancer diagnosis
GANYMED PHARMACEUTICALS AG9 citations82
US9433675B2Sep 6, 2016
Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
GANYMED PHARMACEUTICALS AG5 citations81
US9475867B2Oct 25, 2016
Monoclonal antibodies for treatment of cancer
GANYMED PHARMACEUTICALS AG3 citations73
US10738108B2Aug 11, 2020
Monoclonal antibodies against claudin-18 for treatment of cancer
GANYMED PHARMACEUTICALS AG2 citations72
US9932401B2Apr 3, 2018
Antibodies specific for claudin 6 (CLDN6)
GANYMED PHARMACEUTICALS AG1 citations61
US10414824B2Sep 17, 2019
Genetic products differentially expressed in tumors and the use thereof
GANYMED PHARMACEUTICALS AG0 citations52
US10125196B2Nov 13, 2018
Monoclonal antibodies for treatment of cancer
GANYMED PHARMACEUTICALS AG0 citations52
US9453260B2Sep 27, 2016
Genetic products differentially expressed in tumors and use thereof
GANYMED PHARMACEUTICALS AG0 citations52
US10745477B2Aug 18, 2020
Antibodies specific for claudin 6 (CLDN6)
GANYMED PHARMACEUTICALS AG0 citations51
US10036753B2Jul 31, 2018
Identification of surface-associated antigens for tumor diagnosis and therapy
GANYMED PHARMACEUTICALS AG0 citations51
US9733251B2Aug 15, 2017
Identification of tumour-associated cell surface antigens for diagnosis and therapy
GANYMED PHARMACEUTICALS AG0 citations51
SAHIN UGUR
9 patentsUS9476055B2Oct 25, 2016
Modification of RNA, producing an increased transcript stability and translation efficiency
SAHIN UGUR29 citations93
US9175088B2Nov 3, 2015
Identification of tumor-associated markers for diagnosing or monitoring ovarian cancer
SAHIN UGUR8 citations84
US8975375B2Mar 10, 2015
Identification of tumor-associated antigens for diagnosis and therapy
SAHIN UGUR5 citations84
US9499609B2Nov 22, 2016
Monoclonal antibodies against claudin-18 for treatment of cancer
SAHIN UGUR5 citations83
US9486519B2Nov 8, 2016
Use of FLT3 ligand for enhancing immune responses in RNA immunization
SAHIN UGUR15 citations80
US9637548B2May 2, 2017
Methods and compositions for diagnosis and treatment of cancer
SAHIN UGUR2 citations73
US9090940B2Jul 28, 2015
Identification of surface-associated antigens for tumor diagnosis and therapy
SAHIN UGUR3 citations62
US8716455B2May 6, 2014
Genetic products differentially expressed in tumors and use thereof
SAHIN UGUR0 citations52
US9809815B2Nov 7, 2017
Methods and compositions for diagnosis and treatment of cancer
SAHIN UGUR0 citations49
BIONTECH AG
6 patentsUS9533043B2Jan 3, 2017
Identification of surface-associated antigens for tumor diagnosis and therapy
BIONTECH AG7 citations83
US9267177B2Feb 23, 2016
Identification of tumor-associated cell surface antigens for diagnosis and therapy
BIONTECH AG6 citations83
US11787862B2Oct 17, 2023
Bispecific trivalent antibodies binding to Claudin6 or Claudin18.2 and CD3 for treatment of Claudin expressing cancer diseases
BIONTECH AG3 citations68
US10253373B2Apr 9, 2019
Identification of tumor-associated markers for diagnosis and therapy
BIONTECH AG1 citations62
US9637794B2May 2, 2017
Genetic products differentially expressed in tumors and use thereof
BIONTECH AG0 citations52
US9139880B2Sep 22, 2015
Identification of tumor-associated cell surface antigens for diagnosis and therapy
BIONTECH AG0 citations51
BioNTech SE
3 patentsGANYMED PHARMACEUTICALS GMBH
3 patentsUS10017564B2Jul 10, 2018
Monoclonal antibodies against claudin-18 for treatment of cancer
GANYMED PHARMACEUTICALS GMBH6 citations82
US11395852B2Jul 26, 2022
Therapy involving antibodies against Claudin 18.2 for treatment of cancer
GANYMED PHARMACEUTICALS GMBH0 citations62
US11858988B2Jan 2, 2024
Antibodies specific for claudin 6 (CLDN6)
GANYMED PHARMACEUTICALS GMBH0 citations61
BIONTECH CELL & GENE THERAPIES GMBH
3 patentsUS10370423B2Aug 6, 2019
Claudin-6-specific immunoreceptors and T cell epitopes
BIONTECH CELL & GENE THERAPIES GMBH4 citations69
US12559531B2Feb 24, 2026
Claudin-6-specific immunoreceptors and T cell epitopes
BIONTECH CELL & GENE THERAPIES GMBH0 citations59
US11345731B2May 31, 2022
Claudin-6-specific immunoreceptors and t cell epitopes
BIONTECH CELL & GENE THERAPIES GMBH0 citations59
ASTELLAS PHARMA INC
3 patentsUS11739139B2Aug 29, 2023
Monoclonal antibodies against Claudin-18 for treatment of cancer
ASTELLAS PHARMA INC0 citations62
US11919951B2Mar 5, 2024
Antibodies useful in cancer diagnosis
ASTELLAS PHARMA INC0 citations61
US11279757B2Mar 22, 2022
Antibodies useful in cancer diagnosis
ASTELLAS PHARMA INC0 citations61